Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Visugromab by Catalym for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Visugromab is under clinical development by Catalym and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Visugromab by Catalym for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Visugromab is under clinical development by Catalym and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to...
Visugromab by Catalym for Bladder Cancer: Likelihood of Approval
Visugromab is under clinical development by Catalym and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II...